Vertex Pharma Inks Licensing Agreement To Use CRISPR Therapeutics' Gene Editing Technology

Vertex Advances Inaxaplin Into Phase 2/3 Trial To Treat APOL1-Mediated Kidney Disease

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care.

RTTNews | Před 503 dny

Vertex Receives CHMP Positive Opinion For The First CRISPR/Cas9 Gene-Edited Therapy CASGEVY

Vertex Pharmaceuticals Inc. (VRTX) announced Friday that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the conditional approval of CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

RTTNews | Před 611 dny

CRISPR Therapeutics Says FDA Grants RMAT Designation To CTX130

Biopharmaceutical company CRISPR Therapeutics (CRSP) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130, the Company's wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS).

RTTNews | Před 1054 dny

Vertex Pharma To Acquire ViaCyte For $320 Mln In Cash

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that the company has entered into a definitive agreement under which Vertex will acquire privately-held biotechnology company ViaCyte for $320 million in cash.

RTTNews | Před 1133 dny

Vertex Pharma Says FDA Lifts Clinical Hold On Phase 1/2 Trial Of VX-880 To Treat Type 1 Diabetes

Vertex Pharmaceuticals Inc. (VRTX) announced Tuesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia.

RTTNews | Před 1139 dny

Japan Shares Due For Profit Taking On Monday

The Japan stock market bounced higher again on Friday, one day after snapping the six-day winning streak in which it had surged more than 3,000 points or 7.3 percent. The Nikkei 225 now sits just beneath the 43,380-point plateau although investors are likely to lock in gains on Monday.

RTTNews | Před 15 minutami

South Korea Shares May Be Stuck In Neutral On Monday

Ahead of Friday's holiday for Liberation Day, the South Korea stock market had moved higher in back-to-back sessions, gathering more than 35 points or 1.1 percent along the way. The KOSPI now sits just above the 3,225-point plateau although it m ay spin its wheels on Monday.

RTTNews | Před 30 minutami

Singapore Export Data On Tap For Monday

Singapore will on Monday release July figures for non-oil domestic exports, highlighting a light day for Asia-Pacific economic activity. In June, NODX was up 14.3 percent on month and 13.0 percent on year.

RTTNews | Před 1 h 30 min

EURUSD	1.17058	GBPUSD	1.35551	AUDUSD	0.6507
USDJPY	147.311	USDCAD	1.38146	USDCHF	0.80673